Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : Ocup save search
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
Published: 2022-05-19 (Crawled : 12:00) - biospace.com/
OCUP | News | $1.505 -9.06% -9.97% 380K
|
Health Technology
|
| O: -15.14%
H: 13.51%
C: 10.27%
nyxol topline eye trial positive phase 3
Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis
Published: 2022-03-29 (Crawled : 12:00) - biospace.com/
OCUP | News | $1.505 -9.06% -9.97% 380K
|
Health Technology
|
| O: -12.82%
H: 7.96%
C: -3.91%
nyxol fda trial positive results topline phase 3
Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations
Published: 2022-02-08 (Crawled : 19:00) - biospace.com/
OCUP | News | $1.505 -9.06% -9.97% 380K
|
Health Technology
|
| O: -0.34%
H: 8.47%
C: 8.47%
nyxol trial conference presentation phase 3 enroll
Ocuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of Nyxol Pediatric Trial, and an Investor R&D Day in January
Published: 2022-01-05 (Crawled : 12:30) - globenewswire.com
OCUP | News | $1.505 -9.06% -9.97% 380K
|
Health Technology
|
| O: -0.26%
H: 2.49%
C: -3.93%
nyxol trial phase 3 enroll
Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM)
Published: 2021-11-23 (Crawled : 14:30) - biospace.com/
OCUP | News | $1.505 -9.06% -9.97% 380K
|
Health Technology
|
| O: -0.29%
H: 0.0%
C: 0.0%
nyxol phase 3 trial enroll
Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint
Published: 2021-03-15 (Crawled : 11:00) - globenewswire.com
OCUP | News | $1.505 -9.06% -9.97% 380K
|
Health Technology
|
| O: 16.6%
H: 6.04%
C: -9.6%
phase 3 trial
Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
Published: 2021-01-06 (Crawled : 12:03) - globenewswire.com
OCUP | News | $1.505 -9.06% -9.97% 380K
|
Health Technology
|
| O: 0.0%
H: 1.32%
C: -4.64%
phase 3 trial enroll
Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances
Published: 2021-01-05 (Crawled : 12:03) - globenewswire.com
OCUP | News | $1.505 -9.06% -9.97% 380K
|
Health Technology
|
| O: 1.57%
H: 7.59%
C: 6.19%
phase 3 pharma
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.